Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...
Doctors say early obesity intervention can help prevent later health problems. But prescribing GLP-1s, such as Ozempic and ...
Two new studies identified additional benefits of medications like semaglutide—the active ingredient in Novo Nordisk's ...
On Nov. 26, the Biden administration announced a plan to require Medicare and Medicaid to cover weight loss medications like ...
People who took Zepbound, Eli Lilly’s weight loss drug, shed more pounds than those on Novo Nordisk’s Wegovy in a clinical ...
Novo Nordisk, the manufacturer of Ozempic and Wegovy, has petitioned the Food and Drug Administration (FDA) to add ...
A new crop of evidence — both anecdotal and research based — is pointing to these drugs as a potential option for people ...
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...
Researchers are exploring a novel weight loss drug that shows potential to outperform the critically acclaimed Ozempic by ...
Ozempic and Wegovy might be making it harder for physicians to guide patients toward lifestyle changes − the real key to long ...
Last year’s study in the journal Obesity had revealed that of people prescribed weight-loss drugs, just 44 per cent were ...
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...